Study Protocol

Fertility preservation in young women with cancer

22-06-2018

Version 2.2
<table>
<thead>
<tr>
<th>Protocol ID</th>
<th>S59981</th>
</tr>
</thead>
<tbody>
<tr>
<td>Short title</td>
<td>INCIP fertility substudy</td>
</tr>
<tr>
<td>EudraCT number</td>
<td>n.a.</td>
</tr>
<tr>
<td>Version</td>
<td>2.2</td>
</tr>
<tr>
<td>Date</td>
<td>22-06-2018</td>
</tr>
<tr>
<td>Coordinating investigator/project leader</td>
<td>Prof. dr. Frédéric Amant</td>
</tr>
<tr>
<td></td>
<td>UZ Leuven, Department of Gynaecological Oncology</td>
</tr>
<tr>
<td></td>
<td>Herestraat 49</td>
</tr>
<tr>
<td></td>
<td>3000 Leuven, Belgium</td>
</tr>
<tr>
<td></td>
<td>Phone: +32 16 34 42 73</td>
</tr>
<tr>
<td></td>
<td>Fax: +32 16 34 46 29</td>
</tr>
<tr>
<td></td>
<td>E-mail: <a href="mailto:frederic.amant@uzleuven.be">frederic.amant@uzleuven.be</a></td>
</tr>
<tr>
<td></td>
<td>And</td>
</tr>
<tr>
<td></td>
<td>Netherlands Cancer Institute (NKI) – Antoni van Leeuwenhoek Hospital</td>
</tr>
<tr>
<td></td>
<td>Plesmanlaan 121</td>
</tr>
<tr>
<td></td>
<td>1066 CX Amsterdam, The Netherlands</td>
</tr>
<tr>
<td></td>
<td>E-mail: <a href="mailto:f.amant@nki.nl">f.amant@nki.nl</a></td>
</tr>
<tr>
<td>Dr. Carla Tomassetti</td>
<td></td>
</tr>
<tr>
<td>UZ Leuven, Department of Obstetrics and Gynaecology</td>
<td></td>
</tr>
<tr>
<td>Herestraat 49</td>
<td></td>
</tr>
<tr>
<td>3000 Leuven, Belgium</td>
<td></td>
</tr>
<tr>
<td>Phone: +32 016 34 08 25</td>
<td></td>
</tr>
<tr>
<td>E-mail: <a href="mailto:carla.tomassetti@uzleuven.be">carla.tomassetti@uzleuven.be</a></td>
<td></td>
</tr>
</tbody>
</table>
### Multicenter research

Coordinating centers per country:

<table>
<thead>
<tr>
<th>The Netherlands</th>
<th>Prof. dr. Frédéric Amant</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Dr. C.A.R. Lok</td>
</tr>
<tr>
<td></td>
<td>Center Gynaecologic Oncology Amsterdam</td>
</tr>
<tr>
<td></td>
<td>Netherlands Cancer Institute (NKI)</td>
</tr>
<tr>
<td></td>
<td>Antoni van Leeuwenhoek Hospital</td>
</tr>
<tr>
<td>Dr. I.A. Boere</td>
<td>Department of Medical Oncology</td>
</tr>
<tr>
<td></td>
<td>Erasmus Medical Center, Rotterdam</td>
</tr>
<tr>
<td>Dr. P.B. Ottevanger</td>
<td>Department of Medical Oncology</td>
</tr>
<tr>
<td></td>
<td>University Medical Center St Radboud, Nijmegen</td>
</tr>
<tr>
<td>Dr. P.O. Witteveen</td>
<td>Department of Medical Oncology</td>
</tr>
<tr>
<td></td>
<td>University Medical Center Utrecht</td>
</tr>
<tr>
<td>Prof. Dr. V.A.C. Tjan-Heijnen</td>
<td>Department of Medical Oncology</td>
</tr>
<tr>
<td></td>
<td>Maastricht University Medical Center</td>
</tr>
<tr>
<td>Dr. C.P. Schröder</td>
<td>Department of Medical Oncology</td>
</tr>
<tr>
<td></td>
<td>University Medical Center Groningen</td>
</tr>
<tr>
<td>Dr. J. Kroep</td>
<td>Department of Medical Oncology</td>
</tr>
<tr>
<td></td>
<td>Leiden University Medical Center</td>
</tr>
<tr>
<td>Other</td>
<td>Members from INCIP will in addition be invited and facilitated to participate to this substudy.</td>
</tr>
</tbody>
</table>

| Sponsor | UZ Leuven |
PROTOCOL SIGNATURE SHEET

<table>
<thead>
<tr>
<th>Name</th>
<th>Signature</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Coordinating Investigator/Project leader/Principal Investigators:</td>
<td></td>
<td>22-06-2018</td>
</tr>
<tr>
<td>Prof. dr. F. Amant</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dr. C. Tomassetti</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

PROTOCOL SIGNATURE SHEET PARTICIPATING SITE

<table>
<thead>
<tr>
<th>Authorization of Ethical Committee/IRB</th>
<th>Authorization of Competent Authority</th>
<th>Insurance</th>
<th>Informed consent form</th>
</tr>
</thead>
<tbody>
<tr>
<td>o Not required</td>
<td>o Not required</td>
<td>o Not required</td>
<td>o Not required</td>
</tr>
<tr>
<td>o Required</td>
<td>o Required</td>
<td>o Certificate available</td>
<td>o Required</td>
</tr>
</tbody>
</table>

Name Participating Site & Investigator

<table>
<thead>
<tr>
<th>Declaration</th>
<th>Signature and Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>I hereby agree (1) with this protocol version (2) to submit this protocol version to the Ethical Committee (EC)/IRB or Competent authority, if required (3) to provide access to Prof. Amant upon his request, to the supporting documentation relating to EC/CA approval(s), ICF and insurance, where required.</td>
<td></td>
</tr>
</tbody>
</table>
TABLE OF CONTENTS

1. SUMMARY 7
2. INTRODUCTION AND RATIONALE 8
3. STUDY DESIGN 9
   3.1 Objectives 9
   3.2 Inclusion criteria 9
   3.3 Sample size 9
   3.4 Study procedures 10
4. STUDY POPULATION 10
   4.1 Population (base) 10
   4.2 Inclusion criteria 11
   4.3 Exclusion criteria 12
5. METHODS 12
   5.1 Randomisation, blinding and treatment allocation 12
   5.2 Study procedures 12
   5.3 Withdrawal of individual subjects 12
   5.4 Replacement of individual subjects after withdrawal 12
   5.5 Follow-up of subjects withdrawn from treatment 12
   5.6 Premature termination of the study 12
6. STATISTICAL ANALYSIS 12
7. SAFETY REPORTING 13
   7.1 Section 10 WMO event 13
   7.2 AEs, SAEs and SUSARs 13
      7.2.1 Adverse events (AEs) 13
      7.2.2 Serious adverse events (SAEs) expected 14
   7.3 Data Safety Monitoring Board (DSMB) 14
8. ETHICAL CONSIDERATIONS 15
   8.1 Regulation statement 15
   8.2 Recruitment and consent 15
   8.3 Objection by incapacitated subjects (if applicable) 15
   8.4 Benefits and risks assessment, group relatedness 15
   8.5 Compensation for injury 15
   8.6 Incentives 16
9. ADMINISTRATIVE ASPECTS, MONITORING AND PUBLICATION 16
   9.1 Handling and storage of data and documents 16
   9.2 Amendments 16
   9.3 Public disclosure and publication policy 17
   9.4 Insurance 17
10. COMPENSATION 17
11. REFERENCES 17
LIST OF ABBREVIATIONS AND RELEVANT DEFINITIONS

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>AE</td>
<td>Adverse Event</td>
</tr>
<tr>
<td>AR</td>
<td>Adverse Reaction</td>
</tr>
<tr>
<td>CA</td>
<td>Competent Authority</td>
</tr>
<tr>
<td>CRF</td>
<td>Case Report Form</td>
</tr>
<tr>
<td>CV</td>
<td>Curriculum Vitae</td>
</tr>
<tr>
<td>DSMB</td>
<td>Data Safety Monitoring Board</td>
</tr>
<tr>
<td>EU</td>
<td>European Union</td>
</tr>
<tr>
<td>GCP</td>
<td>Good Clinical Practice</td>
</tr>
<tr>
<td>IC</td>
<td>Informed Consent</td>
</tr>
<tr>
<td>n.a.</td>
<td>Not applicable</td>
</tr>
<tr>
<td>(S)AE</td>
<td>(Serious) Adverse Event</td>
</tr>
<tr>
<td>WMO</td>
<td>Medical Research Involving Human Subjects Act</td>
</tr>
</tbody>
</table>
1. SUMMARY

Rationale:
Cancer is the second leading cause of death during the reproductive years. The long term survival improves for most cancers, reaching 80% for pediatric cancer and more than 70% for cancers in adults between 20 and 49 years of age. Early detection and improvements in cancer treatment contribute to these figures. As a result, quality of life of which preservation of fertility is one aspect, becomes more important. Fertility may however be influenced by surgery and by the gonadotoxic effects of chemotherapy and/or radiotherapy. Therefore, fertility sparing treatments are offered to young patients in order to maintain the wish to conceive after cancer treatment. This however is associated with deviation of standard treatment and many different strategies are applied among different centers. In addition, there is a lack of studies investigating the oncological safety of these fertility sparing treatment protocols. The results of this study will enable us to better inform clinicians and patients on the efficacy of fertility sparing cancer treatment.

Objective:
To record the incidence, treatment and long term follow up of fertility preserving cancer treatment. Both the oncological and fertility outcome are recorded.

Study design: International multicentre prospective observational trial

Study population: All female adults with a cancer for whom a fertility preserving cancer treatment is applied. The results of the study population are compared to young women undergoing standard cancer treatment.

Intervention (if applicable): n.a.

Main study parameters/ endpoints:
Registration of cancer diagnosis, treatment and outcome. Both the oncologic and fertility outcome are registered.

Nature and extent of the burden and risks associated with participation, benefit and group relatedness:
All patients receive fertility sparing cancer treatment on their specific request. Participation in this observational registration study is not associated with burdens or risks, since participation will not alter the treatment regimens.
2. INTRODUCTION AND RATIONALE

Never ending research in cancer treatment and optimization of prevention methods have led to increased survival rates in people diagnosed with cancer. The long term survival improves for most cancers, reaching 80% for pediatric cancers and more than 70% for cancers in adults between 20 and 49 years of age (1). As the prognosis for malignancies improves, the long-term side effects become more important. The focus has switched from a purely oncology point of view towards oncofertility, in which fertility, as one of the major factors for a good quality of life, becomes substantially more important (2).

Decreased ovarian reserve, premature ovarian insufficiency and premature menopause due to surgery and the gonadotoxic effects of chemotherapy and radiotherapy may however result in fertility impairment. As more than 60% of patients with cancer is most concerned about the impact of the treatment on their fertility, fertility sparing treatments should be offered to young patients in order to maintain the wish to conceive after cancer treatment (5).

Counselling and referring patients, who wish to safeguard their reproductive potential, to a fertility center is of great importance as up to 75% of young cancer survivors want to have children (4).

Embryo cryopreservation is the most frequently used intervention to preserve fertility, for patients undergoing a gonadotoxic treatment. Oocyte cryopreservation is less frequently used, but has a similar outcome and could be a good alternative for single women.

Other more experimental alternatives are cryopreservation of ovarian tissue, temporary translocation of the ovaries when pelvic radiotherapy is needed and ovarian function suppression with GnRH-analogues during chemotherapy (5).

Regarding cancer of the female genital tract, in which radical surgery is mostly the standard, alternatives are being investigated to preserve fertility. There are still a lot of gaps in research regarding these fertility sparing surgical treatments and the interventions are often experimental, as there is no standardized technique available due to lack of data. This leads to many different strategies being applied among different centers. In addition, there is a lack of studies investigating the oncological safety and obstetric outcome of these fertility sparing treatment protocols. Another major consequence of the absence of a standard technique is the difficulty to inform patients about the best treatment.

It is important to obtain a significant amount of cases in order to make a thorough study especially since several types of cancer do not occur regularly. It is in this respect that this study aims to fill the gap in current research.

The purpose is to enable us to obtain a significant amount of data to create more standardized fertility sparing treatment protocols and to better inform clinicians and patients on the efficacy of fertility sparing cancer treatment.
3. STUDY DESIGN
The proposed research concerns a multicenter prospective observational cohort study. European collaboration is utilized in order to include sufficient number of patients.

This is a study, for which primary approval was granted by UZ Leuven. UZ Leuven is the initiator of the study and the ethical committee of UZ Leuven is the central ethical committee. The UZ Leuven protocol is used in all centers, including the international collaborators.

3.1 Objectives
Primary Objective:
To record the incidence and oncological outcome when a fertility preserving cancer treatment is applied in young women and compare the oncological outcome with a control group.

Secondary Objective(s):
To record the incidence and fertility outcome when a fertility preserving cancer treatment is applied in young women and compare the obstetrical and neonatal outcome with the general population.

3.2 Inclusion criteria
Histological proven cancer in young women under the age of 40 for whom a fertility preserving cancer treatment is applied. For the control group, patients are eligible when they are in the fertile age but over 18 years of age and undergoing standard cancer treatment.

3.3 Sample size
We aim for at least 500 cases per tumour type + 1 control patient per study patients (resulting in 500 control patients per tumour type). This is a minimum that allows us to calculate the oncological prognosis (secondary objective).
3.4 Study procedures
In women younger than 40 years old with a cancer diagnosis for whom a fertility preserving treatment is applied, the most important oncological data will be registered, as well as information on the fertility and oncological outcome. Control patients are women who are younger than 40 years of age diagnosed with cancer and who received standard treatment. All types of cancer and all types of treatment will be registered. Patients can be included both prospectively and retrospectively. For every study patient, we include one control patient.

Recruitment of patients:
Because information on pregnant state is not available in most cancer registries prospective recruitment of patients is done as followed networking (e.g. INCIP), newsletters, presentation at conferences for obstetricians, oncologists, haematologists, and also a website for professionals (www.cancerinpregnancy.org) and for patients (http://www.uzleuven.be/kanker-en-zwangerschap).

We will collect the following data:
At baseline:
Oncological data include type of cancer, the date of diagnosis, tumour histology, stage of the disease, the type of treatment, cancer recurrence and survival.
Fertility data include gravidity and parity, menstrual pattern after cancer treatment, conception (artificial of natural), obstetrical complications, gestational age at delivery and mode of delivery (induction, caesarean section, spontaneous labour).
Paediatric data that will be collected include birth weight, gender, congenital malformations, admission to neonatal care unit and reason of admission.
Annually until end of study:
We will request information from the treating physician regarding patient’s health status (pregnant yes/no, relapse yes/no, site of relapse, treatment of relapse, date of relapse, date of death if applicable).

This study does not involve any direct input or effort from the patient. Only the collection of existing information through the medical records is aimed for.

4. STUDY POPULATION
4.1 Population (base)
All women under the age of 40 diagnosed with cancer for whom a fertility preserving cancer treatment is applied will be eligible for inclusion.
Fig. 1: Most common cancer in women 15–39 years old. *Incidence rates per 100,000.(6,7)

Fig. 2: Model-based cumulative probabilities of first post diagnosis parenthood. For the young adult diagnostic age group, the curves represent conditional cumulative probability of parenthood given the patient had no children at age 20. The dashed line represents siblings and the solid line represents cancer patients.(8)

4.2 Inclusion criteria
Histological proven cancer in women up to 40 years old but in their fertility years with a wish to preserve their fertility by undergoing fertility preserving cancer treatment.
4.3 Exclusion criteria
A potential subject who meets any of the following criteria will be excluded from participation in this study:
- Mentally disabled or significantly altered mental status that would prohibit the understanding and giving of informed consent.

5. METHODS

5.1 Randomisation, blinding and treatment allocation
n.a.

5.2 Study procedures
For this study, it will not be necessary to postpone diagnostic procedures or treatment. Participation in this study does not influence normal treatment.

5.3 Withdrawal of individual subjects
Subjects can leave the study at any time for any reason and if they wish to do so this will be without any consequences. The investigator can decide to withdraw a subject from the study for urgent medical reasons.

5.4 Replacement of individual subjects after withdrawal
n.a.

5.5 Follow-up of subjects withdrawn from treatment
n.a.

5.6 Premature termination of the study
No reasons for premature termination of the study are anticipated.

6. STATISTICAL ANALYSIS
We plan to use descriptive statistics (mean +/- standard deviation), two-sided tests, and Wilcoxon rank sum test to compare continuous variables in two groups, for more than two groups, the Kruskal-Wallis exact test will be used. For comparing a proportion with an expected value, a binominal exact test will be used. Results are considered significant at P<.05.
Analysis will be performed with SAS (version 9.2) and Statistical Package for Social Sciences for Windows (version 16). Statistical analysis will be performed under supervision of Prof. B. Van Calster (Leuven Cancer Institute, Belgium).

7. SAFETY REPORTING

7.1 Section 10 WMO event

In accordance to section 10, subsection 1, of the WMO, the investigator will inform the subjects and the reviewing accredited ethical committee if anything occurs, on the basis of which it appears that the disadvantages of participation may be significantly greater than was foreseen in the research proposal. The study will be suspended pending further review by the accredited METC, except in so far as suspension would jeopardise the subjects’ health. The investigator will take care that all subjects are kept informed.

7.2 AEs, SAEs and SUSARs

Definitions in Law of May 7, 2004 concerning experiment on the human person

Adverse event (AE): any untoward medical occurrence in a patient or subject of the treated group during an experiment, and which does not necessarily have a causal relationship with this treatment

Serious adverse event (SAE): any untoward medical occurrence or effect that results in death, is life-threatening, requires hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability or incapacity, or is a congenital anomaly or birth defect;

Suspected unexpected serious adverse reaction (SUSAR): is an AR that is serious and unexpected (meaning that nature or severity of the AR is not consistent with the Investigational Medicinal Product reference safety information, which is the Investigator’s Brochure) and is judged by either the investigator or the sponsor as having a reasonable suspected causal relationship with the investigational medicinal product.

7.2.1 Adverse events (AEs)

All adverse events caused by study interventions reported spontaneously by the subject or observed by the investigator or his staff will be recorded. We do not expect any study related adverse events for this study.
7.2.2 Serious adverse events (SAEs) expected

The investigator shall report all study intervention-related serious adverse events immediately, after first knowledge, to the sponsor except for those that the protocol or investigator's brochure identifies as not requiring immediate reporting. The immediate report shall be followed by detailed, written reports. The immediate and follow-up reports shall identify subjects by code numbers. For reported study intervention related deaths of a subject, the investigator shall supply the sponsor and the accredited ethics committee with any additional information requested.

The sponsor shall keep detailed records of all study intervention-related adverse events which are reported to him by the investigator or investigators. These records shall be submitted to the minister if the experiment is being conducted in Belgium, if he so requests. Regarding those study intervention-related serious adverse events the Principal Investigator will take all reasonable measures, in consultation with Sponsor, to protect subjects at risk following the occurrence of such events.

Participation in this study holds an extremely low risk of AEs and study intervention-related SAEs since no invasive interventions are performed. Since this study holds an extremely low risk of a study intervention-related SAE and no invasive interventions are performed, this present study is relieved of reporting non study related SAEs.

7.3 Data Safety Monitoring Board (DSMB)

Data safety monitoring board is not needed. As this study is a study with extremely low risks and does not falls under the scope of the WMO, no monitoring is needed.
8. ETHICAL CONSIDERATIONS

8.1 Regulation statement
This study will be conducted according to the principles of the Declaration of Helsinki (WORLD MEDICAL ASSOCIATION DECLARATION OF HELSINKI) Ethical Principles for Medical Research Involving Human Subjects Version Edinburgh, Scotland, October 2000, with Note of Clarification on paragraph 29 added by the WMA General Assembly, Washington 2002 end note of clarification on paragraph 30 added by the WMA General Assembly, Tokyo 2004 and in accordance with the Medical Research Involving Human Subjects Act (WMO) and other guidelines, regulations and Acts.

8.2 Recruitment and consent
Eligible patients will be informed about the study by the supervising physician (e.g. gynaecologist, surgeon or medical oncologist) primarily treating the malignancy. The patient will also obtain written information about the study. The patient can think about participation and discuss the study with her family. They will be given enough time to consider their decision and are free to reconsider their decision at any moment during the trial. In case of participation the informed consent should be signed prior to registration of patient data. This is applicable for the prospective part of this study. An exception is made for the retrospective part of this registration study; retrospective data without the need for follow-up may be collected anonymously without a signed consent form for evaluation of quality of care since it does not fall under the scope of the WMO.

8.3 Objection by incapacitated subjects (if applicable)
No incapacitated subjects will be included in the study.

8.4 Benefits and risks assessment, group relatedness
As this study will not change treatment nor randomize patients, participation in this study will not affect patients’ outcomes. As this is an observational study, no additional risks from the study are expected.

8.5 Compensation for injury
Participation in this study does not imply any study related actions and only carries negligible risks for the research subjects. However, the sponsor shall be liable, even without fault, for any damages incurred by a study subject and linked directly or indirectly to the participation to the study.
Sponsor shall enter into an insurance agreement in order to cover the liability for any damages incurred by a study subject from a Belgian participating site. See paragraph 9.4 for further information.

8.6 Incentives
Eligible participants do not receive any special incentives that may encourage participation in this study.

9. ADMINISTRATIVE ASPECTS, MONITORING AND PUBLICATION

9.1 Handling and storage of data and documents
The investigator records clinical data, using a paper or electronic case report form (CRF), all data is collected in an online database that is available through www.cancerinpregnancy.org, such database being the ownership of Sponsor. Participating physicians have a personal account to log in to the registration page and access the electronic CRF. They will have permanent access only to their own series of patients. The participating physician ensures the confidentiality, accuracy, completeness, legibility and timeliness of the data recorded. Data handling and statistical analysis will be done anonymously by the investigator, with the subject identification code list only available to the local investigator (and research nurse if applicable) working in the local center. The code will be based on the birth date and center abbreviation (and not patient initials). The investigator will be the owner of the data. Data will be kept for 20 years.

Sponsor, participating physicians and sites agree and commit to handle and protect the data in accordance with the terms and provisions of all applicable data protection rules and legislation including the Belgian law of 08 December 1992 on Privacy Protection in relation to the Processing of Personal Data and the Belgian law of 22 August 2002 relating to patient’s rights.

9.2 Amendments
Amendments are changes made to the research after a favourable opinion by the accredited ethical committee has been given. All amendments will be notified to the ethical committee that gave a favourable opinion.
A ‘substantial amendment’ is defined as an amendment to the terms of the ethical committee application, or to the protocol or any other supporting documentation, that is likely to affect to a significant degree:
- the safety or physical or mental integrity of the subjects of the trial;
- the scientific value of the trial;
- the conduct or management of the trial; or
- the quality or safety of any intervention used in the trial.

All substantial amendments will be notified to the ethical committee and to the competent authority. Non-substantial amendments will not be notified to the accredited ethical committee and the competent authority, but will be recorded and filed by the sponsor.

### 9.3 Public disclosure and publication policy

This study is registered with ClinicalTrials.gov, number NCT02878434.

All publications from this study will be done by the principle investigators and other investigators according to their contribution to this study.

### 9.4 Insurance

Sponsor shall be liable, even without fault, for any damages incurred by a study subject and linked directly or indirectly to the participation to the study.

Sponsor shall enter into an insurance agreement in order to cover the liability for any damages incurred by a study subject from a Belgian participating site.

If an insurance coverage is required by local laws of non-Belgian participating sites, such participating sites shall have and maintain in full force and effect during the term of this Agreement (and following termination of the study to cover any claims arising from the study) adequate insurance coverage for any damages linked directly or indirectly to the subjects’ participation to the study at participating sites. Participating sites shall provide a corresponding insurance certificate to Sponsor.

### 10. REFERENCES


11. APPENDIX A

DATA PROCESSING ANNEX (“DPA”) TO THE PROTOCOL

Definitions:

“Protocol” means the document entitled “Fertility Preservation” containing the details of the academic study as developed by the Sponsor as approved by the relevant ethics committee.

“Sponsor” means Universitaire Ziekenhuizen Leuven.

Participating site acts as a data processor as defined under article 4, 8) of the Regulation (EU) 2016/679 (“Data Processor”) for the Sponsor who acts as data controller as defined under article 4, 7) of the Regulation (EU) 2016/679 (“Data Controller”).

“Applicable Law” means any applicable data protection or privacy laws, including:

(i) the Regulation (EU) 2016/679 also referred as the General Data Protection Regulation ("GDPR");

(ii) other applicable laws that are similar or equivalent to or that are intended to or implement the laws that are identified in (a) of this definition;

"Personal Data" means any information relating to an identified or identifiable natural person (‘Data Subject’), including without limitation pseudonymized information, as defined in Applicable Law and described in the Protocol.

Rights and obligations:

1) The Data Processor is instructed to process the Personal Data for the term of the Protocol and only for the purposes of providing the data processing tasks set out in the Protocol.

2) The Data Processor must ensure that persons authorized to process the Personal Data have committed themselves to confidentiality or are under an appropriate statutory obligation of confidentiality.

3) The Data Processor shall implement appropriate technical and organizational measures to prevent that the Personal Data processed is:

(i) accidentally or unlawfully destroyed, lost or altered,

(ii) disclosed or made available without authorization, or

(iii) otherwise processed in violation of Applicable Law.

4) The appropriate technical and organizational security measures must be determined with due regard for:

(i) the current state of the art,

(ii) the cost of their implementation, and

(iii) the nature, scope, context and purposes of processing as well as the risk of varying likelihood and severity for the rights and freedoms of natural persons.

5) The Data Processor shall upon request provide the Data Controller with sufficient information to enable the Data Controller to ensure that the Data Processor's obligations under this DPA are complied with, including ensuring that the appropriate technical and organizational security measures have been implemented.

6) The Data Controller is entitled to appoint at its own cost an independent expert, reasonably acceptable to Data Processor, who shall have access to the Data Processor's data processing facilities and receive the necessary information for the sole purpose of auditing whether the Data Processor has implemented and maintained said technical and organizational security measures. The expert shall upon the Data Processor's request
sign a non-disclosure agreement provided by the Data Processor, and treat all information obtained or received from the Data Processor confidentially, and may only pass on, after conferral with Data Processor, the findings as described under 8) (ii) below to the Data Controller.

7) The Data Processor must give authorities who by Union or Member State law have a right to enter the Data Controller's or the Data Controller's processors’ facilities, or representatives of the authorities, access to the Data Processor's physical facilities against proper proof of identity and mandate, during normal business hours and upon reasonable prior written notice.

8) The Data Processor must without undue delay in writing notify the Data Controller about:
   (i) any request for disclosure of Personal Data processed under the Protocol by authorities, unless expressly prohibited under Union or Member State law,
   (ii) any finding of (a) breach of security that results in accidental or unlawful destruction, loss, alteration, unauthorized disclosure of, or access to, Personal Data transmitted, stored or otherwise processed by the Data Processor under the Protocol, or (b) other failure to comply with the Data Processor's obligations, or
   (iii) any request for access to the Personal Data (with the exception of medical records for which the Data Processor is considered data controller) received directly from the data subjects or from third parties.

9) Such a notification from the Data Processor to the Data Controller with regard to a breach of security as meant in 8) (ii)(a) above will contain at least the following information:
   (i) The nature of the Personal Data breach, stating the categories and (by approximation) the number of Data Subjects concerned, and stating the categories and (by approximation) the number of the personal data registers affected (datasets);
   (ii) The likely consequences of the Personal Data breach;
   (iii) A proposal for measures to be taken to address the Personal Data breach, including (where appropriate) measures to mitigate any possible adverse effects of such breach.

10) The Data Processor shall document (and shall keep such documentation available for the Data Controller) any Personal Data breaches, including the facts related to the Personal Data breach, its effects and the corrective measures taken. After consulting with the Data Controller, the Data Processor shall take any measures needed to limit the (possible) adverse effects of Personal Data breaches (unless such consultation cannot be awaited due to the nature of the Personal Data breach).

11) The Data Processor must promptly reasonably assist the Data Controller (with the handling of (a) responses to any breach of security as described in 8) (ii) above and (b) any requests from Data Subjects under Chapter III of the GDPR (upon its entry into force), including requests for access, rectification, blocking or deletion. The Data Processor must also reasonably assist the Data Controller by implementing appropriate technical and organizational measures for the fulfilment of the Data Controller's obligation to respond to such requests. The Data Processor must reasonably assist the Data Controller with meeting the other obligations that may be incumbent on the Data Controller according to Union or Member State law where the assistance of the Data
Processor is implied, and where the assistance of the Data Processor is necessary for the Data Controller to comply with its obligations. This includes, but is not limited to, at the request to provide the Data Controller with all necessary information about an incident under 8) (ii), and all necessary information for an impact assessment in accordance with Article 35 and Article 36 of the GDPR.

Subprocessor:

12) The Data Processor may only engage a subprocessor, with prior specific or general written consent from the Data Controller. The Data Processor undertakes to inform the Data Controller of any intended changes concerning the addition or replacement of a subprocessor by providing a reasonable prior written notice to the Data Controller. The Data Controller may reasonably and in a duly substantiated manner object to the use of a subprocessor. The Data Processor must inform the Data Controller in writing of the discontinued use of a subprocessor.

13) Prior to the engagement of a subprocessor, the Data Processor shall conclude a written agreement with the subprocessor, in which at least the same data protection obligations as set out in this DPA shall be imposed on the subprocessor, including obligations to implement appropriate technical and organizational measures and to ensure that the transfer of Personal Data is done in such a manner that the processing will meet the requirements of the Applicable Law.

14) The Data Controller has the right to receive a copy of the relevant provisions of Data Processor's agreement with the subprocessor related to data protection obligations. The Data Processor shall remain fully liable to the Data Controller for the performance of the subprocessor obligations under this DPA. The fact that the Data Controller has given consent to the Data Processor's use of a subprocessor is without prejudice for the Data Processor's duty to comply with this DPA.